A new study has found that younger people show measurably higher biological ages than older generations at the same chronological age.
A new study led by researchers at Washington University School of Medicine in St. Louis provides evidence that younger generations are indeed aging faster biologically than their older counterparts. The causes remain under investigation around the world, including global efforts led by research members of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, and Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute and Cancer Research U.K.; but importantly, the new research links this accelerated aging to an increased risk of early-onset cancers in younger generations. In general, early-onset cancers are those diagnosed at age 55 or younger.
The larger the gap between biological age — that is, how old our bodies appear to be — and chronological age — which is how many years we have actually lived — the higher the cancer risk, according to the researchers. They found that people in more recent birth cohorts had larger age gaps than those in older birth cohorts, which may help explain the rise in early-onset cancer in recent generations.
Their study also identified links between faster aging in particular organ systems and increased risks for certain cancers. For instance, an immune system that appears older than its actual age was associated with early-onset lung cancer. Similarly, fat tissue that appears older than its chronological age was associated with early-onset colorectal cancer.
Luo et al. present TRACER, a transcriptome-wide approach to identify RNA elements that recruit the CCR4-NOT complex. TRACER uncovers thousands of CCR4-NOT-associated elements, many mapping to known or predicted RBP and miRNA target sites. These elements drive mRNA repression and can be targeted using gene editing or ASO approaches.
Life Biosciences just dosed the first human patient with ER-100 — an OSK gene therapy built from three Yamanaka factors, designed to reprogram old cells back toward a younger state. The first target is the eye. But the real implication is much bigger: this method appears to work on every tissue type it has been tried on.
If this first eye trial comes back safe, it could be the first domino in a much larger age-reversal wave: eye, liver, brain, skin, muscle, heart, kidney, blood vessels — potentially every tissue in the body.
This episode reveals the tidal wave of companies racing toward human trials using the same basic strategy: epigenetically reprogramming old cells so they behave young again. Billions of dollars are pouring into this from Jeff Bezos, Sam Altman, Brian Armstrong, Peter Thiel, and the biggest names in longevity biotech.
We walk through who they are, what they are trying to cure, why the eye came first, what worked in mice and monkeys, why NewLimit is going after liver rejuvenation, and whether the cheap pill version could be right behind the expensive gene therapy.
Bottom line: real age reversal is now in a human trial.
LONGEVITY LATTE PRE-ORDER:
The tech world is standing at the edge of a massive shift in how software is built. For decades, bringing an idea to life meant getting bogged down in rigid syntax and manual coding.
But what if you could essentially just talk your software into existence? Welcome to the dawn of the “Vibecoding” era—a space where I believe we are moving past traditional engineering and into the seamless orchestration of human intent.
Instead of hunting for syntax errors on flat screens, imagine an immersive environment where you collaborate with AI to instantly capture the core “vibe” of your idea.
The system takes your conversational guidance and simultaneously synthesizes beautiful user interfaces and robust backend architectures. It’s an absolute game-changer, especially for founders wanting to spin up a production-ready MVP for an investor pitch in just a single afternoon without writing a single line of code.
I just published a new article exploring how this shift is completely reshaping the way I look at the creative lifecycle—from the initial spark of an idea to macro-scale, global digital infrastructures.
Click the link below to read the full breakdown. I’d love to hear your thoughts on where you think this is heading!
Gödel’s Mind: How AI Agents Emerged from a Logical Paradox.
The Gödel Agent, a new AI research paper, represents a novel paradigm in self-referential AI agents by leveraging recursive self-improvement inspired by the Gödel machine. Traditional agentic systems have been constrained by human design, either through hand-crafted algorithms or pre-defined meta-learning routines, limiting the scope of optimization. The Gödel Agent framework bypasses these limitations by allowing agents to modify not only their decision-making policies but also their meta-learning algorithms dynamically and autonomously. The self-referential nature of Gödel Agent enables it to modify its own code during runtime, thereby continuously evolving without predefined constraints or bottlenecks imposed by human-designed modules.
Central to the Gödel Agent’s methodology is its use of large language models (LLMs) that drive recursive decision-making and self-modification. The agent operates by analyzing its performance in the environment, retrieving its current codebase from runtime memory, and employing monkey patching to alter its behavior. This process of \.
The evolutionary imperatives of survival and procreation, and their associated rewards, are driving life as most animals know it. Perhaps uniquely, humans are able to consciously experience these pleasures and even contemplate the elusive prospect of happiness. The advanced human ability to consciously predict and anticipate the outcome of choices and actions confers on our species an evolutionary advantage, but this is a double-edged sword, as John Steinbeck pointed out as he wrote of “the tragic miracle of consciousness” and how our “species is not set, has not jelled, but is still in a state of becoming” (Steinbeck and Ricketts 1941). While consciousness allows us to experience pleasures, desires, and perhaps even happiness, this is always accompanied by the certainty of the end.
Nevertheless, while life may ultimately meet a tragic end, one could argue that if this is as good as it gets, we might as well enjoy the ride and in particular to maximize happiness. Yet, it is also true that for many happiness is a rare companion due to the competing influences of anxiety and depression.
In order to help understand happiness and alleviate the suffering, neuroscientists and psychologists have started to investigate the brain states associated with happiness components and to consider the relation to well-being. While happiness is in principle difficult to define and study, psychologists have made substantial progress in mapping its empirical features, and neuroscientists have made comparable progress in investigating the functional neuroanatomy of pleasure, which contributes importantly to happiness and is central to our sense of well-being.
You know how rejuvenating a bath feels after a long day of work? Almost like you’re renewed. Turns out that’s not exclusive to humans. Scientists at Cornell University have developed an electrochemical bath that restores spent lithium-ion batteries to nearly 100% capacity.
Unlike conventional battery recycling methods that involve the complete physical destruction of batteries, followed by complex, energy-intensive recovery processes to extract critical battery-making materials, the scientists’ method recycles lithium-ion battery electrodes directly. Rather than breaking down structurally intact electrodes to extract materials that will make other electrodes, their approach regenerates the existing electrodes using an electrochemical solution.
The researchers say this method restored batteries to 95% of their original capacity, and even helped recycled batteries last longer. According to them, the method could also slash recycling costs by 56% while being more environmentally friendly.